| HOME >> MEDICINE >> TECHNOLOGY |
Approved Indications for Pradaxa in Select Regions II-13
Rivaroxaban (Xarelto) II-13
Approved Indications for Xarelto in Select Regions II-14
Xarelto Patent Expiration in Various Regions II-14
Apixaban (Eliquis) II-15
Betrixaban II-15
Comparison of Select Approved and Pipeline Anticoagulant
Agents in a Nutshell II-15
Market Dynamics II-16
New Oral Drugs More Efficacious In Reducing Stroke II-16
New Generation Anticoagulants Enter the Market, Warfarin
Comes Under Pressure II-16
Oral Anticoagulants Market to Witness Intense Competition II-16
Pradaxa- A High Potential Replacement to Warfarin II-17
Packaging May Hurt Pradaxa's Prospects II-17
New Oral Drugs in Various Indications II-17
Emerging Targets in the Anticoagulation Space II-18
Daiichi Sankyo Upbeat on Prospects of Edoxaban II-18
ELIQUIS' FDA Approval Faces Further Delays II-19
The ARISTOTLE Trial II-19
Eliquis - More Promising than Existing Oral Anticoagulants II-20
Competitors Capitalize on Delay in Eliquis' Approval II-20
Do New Oral Anticoagulants Circumvent Issues with
Conventional Drugs? II-20
Hemostatic Agents for Reversing Action of New Oral Drugs - An
Area Demanding Active Research II-21
4. INJECTABLE ANTICOAGULANTS II-22
Injectable Anticoagulants- An Insight II-22
Heparin - The Back Bone of Injectable Anticoagulants II-22
Unfractionated Heparin II-22
Advantages and Alternatives II-23
Limitations II-23
Low Molecular Weight Heparins II-23
Indications II-24
Advantages II-24
Contraindications II-25
Side Effects II-25
Caution II-25
Costs II-25
Impediments II-25
A Focus on Select Heparin Based Injectables II-26
Lovenox/Clexane (enoxaparin) II-26
Approved Indications fo
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |